- Home
- GLV vs BEAT Comparison
GLV vs BEAT Comparison
Compare GLV & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLV
- BEAT
- Stock Information
- Founded
- GLV 2004
- BEAT 2015
- Country
- GLV United States
- BEAT United States
- Employees
- GLV N/A
- BEAT N/A
- Industry
- GLV Finance/Investors Services
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- GLV Finance
- BEAT Technology
- Exchange
- GLV Nasdaq
- BEAT Nasdaq
- Market Cap
- GLV 63.4M
- BEAT 59.0M
- IPO Year
- GLV N/A
- BEAT 2021
- Fundamental
- Price
- GLV $5.44
- BEAT $1.77
- Analyst Decision
- GLV
- BEAT Buy
- Analyst Count
- GLV 0
- BEAT 1
- Target Price
- GLV N/A
- BEAT $8.00
- AVG Volume (30 Days)
- GLV 54.2K
- BEAT 53.6K
- Earning Date
- GLV 01-01-0001
- BEAT 05-13-2025
- Dividend Yield
- GLV 12.44%
- BEAT N/A
- EPS Growth
- GLV N/A
- BEAT N/A
- EPS
- GLV N/A
- BEAT N/A
- Revenue
- GLV N/A
- BEAT N/A
- Revenue This Year
- GLV N/A
- BEAT N/A
- Revenue Next Year
- GLV N/A
- BEAT N/A
- P/E Ratio
- GLV N/A
- BEAT N/A
- Revenue Growth
- GLV N/A
- BEAT N/A
- 52 Week Low
- GLV $4.70
- BEAT $1.45
- 52 Week High
- GLV $6.06
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- GLV 57.01
- BEAT 47.28
- Support Level
- GLV $5.39
- BEAT $1.78
- Resistance Level
- GLV $5.48
- BEAT $1.91
- Average True Range (ATR)
- GLV 0.12
- BEAT 0.14
- MACD
- GLV 0.02
- BEAT 0.02
- Stochastic Oscillator
- GLV 53.23
- BEAT 38.01
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.